Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) Revenue (2020 - 2025)

Fennec Pharmaceuticals filings provide 4 years of Revenue readings, the most recent being $13.8 million for Q4 2025.

  • On a quarterly basis, Revenue rose 73.84% to $13.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $44.6 million, a 6.09% decrease, with the full-year FY2025 number at $44.6 million, down 6.09% from a year prior.
  • Revenue hit $13.8 million in Q4 2025 for Fennec Pharmaceuticals, up from $12.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $25.4 million in Q1 2024 to a low of $1.7 million in Q1 2023.
  • Median Revenue over the past 3 years was $8.3 million (2024), compared with a mean of $9.5 million.
  • Biggest five-year swings in Revenue: soared 1413.24% in 2024 and later plummeted 65.52% in 2025.
  • Fennec Pharmaceuticals' Revenue stood at $9.7 million in 2023, then dropped by 18.59% to $7.9 million in 2024, then soared by 73.84% to $13.8 million in 2025.
  • The last three reported values for Revenue were $13.8 million (Q4 2025), $12.5 million (Q3 2025), and $9.7 million (Q2 2025) per Business Quant data.